These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 714112)

  • 1. Hyperglucagonemia in diabetes.
    N Engl J Med; 1978 Dec; 299(24):1366-8. PubMed ID: 714112
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.
    Gerich JE; Schultz TA; Lewis SB; Karam JH
    Diabetologia; 1977 Sep; 13(5):537-44. PubMed ID: 908478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.
    Wahren J
    Lancet; 1976 Dec; 2(7997):1213-6. PubMed ID: 63040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics.
    Gerich JE; Lorenzi M; Schneider V; Kwan CW; Karam JH; Guillemin R; Forsham PH
    Diabetes; 1974 Nov; 23(11):876-80. PubMed ID: 4430415
    [No Abstract]   [Full Text] [Related]  

  • 5. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.
    Scheen AJ; Krzentowski G; Castillo M; Lefèbvre PJ; Luyckx AS
    Diabetologia; 1983 May; 24(5):319-25. PubMed ID: 6135635
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of hyperglucagonaemia on blood glucose concentrations and on insulin requirements during fasting in insulin dependent diabetes mellitus.
    Clarke WL; Melton TW; Bright GM
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):557-60. PubMed ID: 6342325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-induced increase in plasma potassium levels in type 1 (insulin-dependent) diabetic subjects.
    Cagliero E; Martina V; Massara F; Molinatti GM
    Diabetologia; 1983 Feb; 24(2):85-7. PubMed ID: 6132848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of somatostatin in maturity-onset diabetes.
    Tamborlane WV; Sherwin RS; Hendler R; Felig P
    N Engl J Med; 1977 Jul; 297(4):181-3. PubMed ID: 876274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus.
    Clarke WL; Santiago JV; Kipnis DM
    Diabetes; 1978 Jun; 27(6):649-52. PubMed ID: 658610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.
    Gerich JE; Lorenzi M; Schneider V; Karam JH; Rivier J; Guillemin R; Forsham PH
    N Engl J Med; 1974 Sep; 291(11):544-7. PubMed ID: 4604408
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.
    Raskin P; Unger RH
    N Engl J Med; 1978 Aug; 299(9):433-6. PubMed ID: 683275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin in maturity-onset diabetes.
    Christensen SE; Hansen AP; Lundbaek K
    Diabetes; 1978 Oct; 27(10):1013-9. PubMed ID: 700257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma.
    Leichter SB; Pagliara AS; Grieder MH; Pohl S; Rosai J; Kipnis DM
    Am J Med; 1975 Feb; 58(2):285-93. PubMed ID: 46704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Somatostatin--a hypothalamic factor inhibiting the secretion of growth hormone].
    Lankosz-Lauterbach J
    Pediatr Pol; 1977 Aug; 52(8):919-23. PubMed ID: 333364
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.
    Sherwin RS; Fisher M; Hendler R; Felig P
    N Engl J Med; 1976 Feb; 294(9):455-61. PubMed ID: 1246330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exogenous hyperglucagonemia in insulin-treated diabetics.
    Raskin P; Unger RH
    Diabetes; 1977 Nov; 26(11):1034-9. PubMed ID: 410690
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of somatostatin added to insulin in a glucose-controlled insulin infusion system.
    Selam JL; Chenon D; Pham TC; Gagnol JP; Sany C; Thomas N; Gravagne G; Orsetti A; Mirouze J
    Diabetologia; 1981 Aug; 21(2):126-30. PubMed ID: 6114891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-induced hypoglycemia is not aggravated by somatostatin in insulin-dependent diabetes.
    Assan R; Heuclin C; Girard JR; Reach G; Basdevant A; Predine J
    Diabete Metab; 1979 Sep; 5(3):189-94. PubMed ID: 499633
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics.
    Raskin P; Unger RH
    Diabetes; 1978 Apr; 27(4):411-9. PubMed ID: 640246
    [No Abstract]   [Full Text] [Related]  

  • 20. Inappropriate counter-regulatory hormone levels in insulin treated diabetes.
    Danowski TS; Fisher ER; Kozak W; Bahl VK; Stephan T; Nolan S; Ahmad U
    Behav Neuropsychiatry; 1976 Apr-1977 Mar; 8(1-12):6-15. PubMed ID: 1052263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.